The 2026 Maui Derm Hawaii conference included a session titled ‘Pediatric Dermatology 2026,’ during which a panel of pediatric dermatologists touched on the latest data in pediatric dermatology, including new drugs and therapies for pediatric patients.1In a new interview filmed on-site at Maui Derm, the HCPLive editorial team spoke with Dawn Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and assistant clinical professor of dermatology at UC San Diego School of Medicine. Eichenfield spoke with HCPLive about some of the most notable takeaways from her talk, as well as related questions in the pediatric dermatology space. The following Q&A interview is a transcript of her questions and answers:HCPLive: What are the most meaningful changes in pediatric dermatology practice that clinicians should be aware of heading into 2026? Eichenfield: I think that what is really exciting about pediatric dermatology is the number of treatments and therapeutics that we now have available for our kids. So there's lots of changes in pediatric dermatology genetic disease, where we're kind of focusing a lot more on the gene and less on the clinical presentation.